



## Clinical trial results:

### Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

#### Summary

EudraCT number	2009-016142-44
Trial protocol	DE AT
Global end of trial date	02 October 2016

#### Results information

Result version number	v1 (current)
This version publication date	22 October 2017
First version publication date	22 October 2017

#### Trial information

##### Trial identification

Sponsor protocol code	AMLSG 12-09
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01180322
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	University Hospital of Ulm
Sponsor organisation address	Albert-Einstein-Allee 23, Ulm, Germany, 89081
Public contact	Prof. Dr. Richard Schlenk, University Hospital of Ulm, 0049 73150045980, richard.schlenk@nct-heidelberg.de
Scientific contact	Prof. Dr. Richard Schlenk, University Hospital of Ulm, 0049 73150045980, richard.schlenk@nct-heidelberg.de

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	17 August 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	02 October 2016
Global end of trial reached?	Yes
Global end of trial date	02 October 2016
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

Primary Efficacy Objective

- To evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate

Secondary Efficacy Objectives

- To evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on RFS, EFS and OS
- To evaluate the impact of 5-azacytidine maintenance therapy in patients achieving a CR on RFS and OS
- To evaluate the efficacy of lenograstim based on duration of neutro- and leukopenia as well as incidence of infection and duration of hospitalization after consolidation therapy
- Assessment of quality of life

Safety Objectives

- Evaluation of safety based on toxicity induced by 5-azacytidine

---

Protection of trial subjects:

In this study, safety was assessed by evaluating the following: reported adverse events, clinical laboratory test results, vital signs measurements, ECG findings, chest X-ray, echo scan, physical examination findings, monitoring of concomitant therapy. For each safety parameter, all findings (whether normal or abnormal) were recorded in the CRF.

---

Background therapy: -

---

Evidence for comparator: -

Actual start date of recruitment	22 October 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Austria: 21
Country: Number of subjects enrolled	Germany: 256
Worldwide total number of subjects	277
EEA total number of subjects	277

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	161
From 65 to 84 years	116
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

First Patient in: 22.10.2010

Last Patient in: 03.04.2012

Recruitment was not interrupted, but randomization into Treatment arms B and C was stopped with effective date 16 September 2011 due to insufficient efficacy.

### Pre-assignment

Screening details:

Molecular genetic analysis (central AMLSG reference lab) of blood and bone marrow was performed at baseline within 48 hours to make an enrollment possible.

### Pre-assignment period milestones

Number of subjects started	277
----------------------------	-----

Number of subjects completed	268
------------------------------	-----

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Violation of inclusion/exclusion criteria: 6
----------------------------	--

Reason: Number of subjects	Consent withdrawn by subject: 2
----------------------------	---------------------------------

Reason: Number of subjects	Other: 1
----------------------------	----------

### Period 1

Period 1 title	Overall trial (overall period)
----------------	--------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Randomised - controlled
-------------------	-------------------------

Blinding used	Not blinded
---------------	-------------

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Arm A: Standard
-----------	-----------------

Arm description: -

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Cytarabine
--	------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Concentrate and solvent for solution for infusion
----------------------	---

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by continuous IV infusion on days 1-7 (total dose 700 mg/m<sup>2</sup>)

Consolidation therapy: Younger adults (18 to 65 yrs): 3 g/m<sup>2</sup>/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m<sup>2</sup>).

Elderly patients (>65 yrs): 1 g/m<sup>2</sup>/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m<sup>2</sup>).

Investigational medicinal product name	Idarubicine
--	-------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Concentrate and solvent for solution for infusion
----------------------	---

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Induction therapy cycle 1: 12 mg/m<sup>2</sup>/day by IV push on days 1,3,5 (total dose 36 mg/m<sup>2</sup>). For elderly

(>65 yrs) patients only two doses of idarubicin were foreseen on days 1+3.  
 Induction therapy cycle 2: 12 mg/m<sup>2</sup>/day by IV push on days 1 and 3 (total dose 24 mg/m<sup>2</sup>; for all age groups).

Investigational medicinal product name	Etoposide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m<sup>2</sup>). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide were foreseen on days 1+3.

<b>Arm title</b>	Arm B: Aza prior
------------------	------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Azacididine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder, dispersion and solvent for concentrate for dispersion for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by SC injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m<sup>2</sup>). Azacididine was given prior to idarubicin and etoposide.

Investigational medicinal product name	Idarubicine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy cycle 1: 12 mg/m<sup>2</sup>/day by IV push on days 6, 8 10 (total dose 36 mg/m<sup>2</sup>). For elderly (>65 yrs) patients only two doses of idarubicin were foreseen on days 6+8.  
 Induction therapy cycle 2: 12 mg/m<sup>2</sup>/day by IV push on days 6 and 8 (total dose 24 mg/m<sup>2</sup>; for all age groups).

Investigational medicinal product name	Etoposide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m<sup>2</sup>). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide were foreseen on days 6+8.

<b>Arm title</b>	Arm C: Aza concurrent
------------------	-----------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Azacididine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder, dispersion and solvent for concentrate for dispersion for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by SC injection or 15-minute IV infusion on days 1-5 (total dose 500 mg/m<sup>2</sup>). Azacididine was given prior to idarubicin and etoposide..

Investigational medicinal product name	Idarubicine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy cycle 1: 12 mg/m<sup>2</sup>/day by IV push on days 1,3,5 (total dose 36 mg/m<sup>2</sup>). For elderly (>65 yrs) patients only two doses of idarubicin were foreseen on days 1+3.  
Induction therapy cycle 2: 12 mg/m<sup>2</sup>/day by IV push on days 1 and 3 (total dose 24 mg/m<sup>2</sup>; for all age groups).

Investigational medicinal product name	Etoposide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m<sup>2</sup>). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide were foreseen on days 1+3.

<b>Arm title</b>	Arm D: Aza after
------------------	------------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Azacitidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder, dispersion and solvent for concentrate for dispersion for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m<sup>2</sup>). Azacitidine was given prior to idarubicin and etoposide.

Investigational medicinal product name	Idarubicine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy cycle 1: 12 mg/m<sup>2</sup>/day by IV push on days 1,3,5 (total dose 36 mg/m<sup>2</sup>). For elderly (>65 yrs) patients only two doses of idarubicin were foreseen on days 1+3.  
Induction therapy cycle 2: 12 mg/m<sup>2</sup>/day by IV push on days 1 and 3 (total dose 24 mg/m<sup>2</sup>; for all age groups).

Investigational medicinal product name	Etoposide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Induction therapy: 100 mg/m<sup>2</sup>/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m<sup>2</sup>). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide were foreseen on days 1+3.

<b>Number of subjects in period 1<sup>[1]</sup></b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent
Started	100	35	34
Completed	39	6	5
Not completed	61	29	29
Adverse event, serious fatal	4	3	2
Consent withdrawn by subject	2	-	1
Adverse event, non-fatal	11	4	1
Other	4	-	1
Lack of efficacy	40	22	24

<b>Number of subjects in period 1<sup>[1]</sup></b>	Arm D: Aza after
Started	99
Completed	22
Not completed	77
Adverse event, serious fatal	8
Consent withdrawn by subject	2
Adverse event, non-fatal	7
Other	3
Lack of efficacy	57

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Of the 277 patients who were enrolled to the study 9 patients were excluded due to violation of inclusion/exclusion criteria (n=6: no presence of AML n=3, AML with NPM1 mutation n=1, presence of Philadelphia chromosome n=1, organ insufficiency (renal failure) n=1), withdrawal of informed consent (n=2) and other reason (extramedullary manifestation of AML in spleen, n=1).

## Baseline characteristics

### Reporting groups

Reporting group title	Arm A: Standard
Reporting group description: -	
Reporting group title	Arm B: Aza prior
Reporting group description: -	
Reporting group title	Arm C: Aza concurrent
Reporting group description: -	
Reporting group title	Arm D: Aza after
Reporting group description: -	

Reporting group values	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent
Number of subjects	100	35	34
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous			
Units: years			
median	62.6	63.5	63.6
full range (min-max)	19 to 81	20 to 79	36 to 82
Gender categorical			
Units: Subjects			
Female	51	14	20
Male	49	21	14
ECOG Performance Status			
Units: Subjects			
ECOG 0	42	16	13
ECOG 1	53	16	20
ECOG 2	5	3	1
Type of AML			
Units: Subjects			
De Novo AML	73	24	24
sAML	16	8	8
tAML	11	3	2
CEBPA mutation status			
Units: Subjects			
Wildtype	82	28	29
Single mutation	4	0	0

Double mutation	7	1	1
Not recorded	7	6	4
DNMT3A mutation status			
Units: Subjects			
Wildtype	76	23	24
Mutation	17	6	6
Not recorded	7	6	4
ASXL1 mutation status			
Units: Subjects			
Wildtype	66	22	26
Mutation	16	5	2
Not recorded	18	8	6
RUNX1 mutation status			
Units: Subjects			
Wildtype	78	19	21
Mutation	15	8	9
not recorded	7	8	4
IDH1 mutation status			
Units: Subjects			
Wildtype	79	24	26
Mutation	13	3	3
not recorded	8	8	5
IDH2 mutation status			
Units: Subjects			
Wildtype	77	25	23
Mutation	5	3	6
not recorded	18	7	5
ELN 2010 classification			
Units: Subjects			
Favorable	7	1	0
Intermediate-I	31	9	11
Intermediate-II	16	12	9
Adverse	30	11	5
not applicable	16	2	9
Hemoglobin (g/dl)			
Units: g/dl			
median	9.1	9.8	9.6
full range (min-max)	5.2 to 12.9	5.9 to 12.9	6.9 to 13.6
Platelets (G/l)			
Units: G/l			
median	64.5	61	53
full range (min-max)	3 to 419	16 to 1286	12 to 301
White blood count (G/l)			
Units: G/l			
median	3.0	3.4	3.6
full range (min-max)	0.4 to 186.0	0.8 to 155.2	0.6 to 141.3
Bone marrow blasts (%)			
Units: percent			
median	53	63.5	61.5
full range (min-max)	0 to 100	10 to 100	20 to 93
Peripheral blood blasts (%)			

Units: percent			
median	12	16	5
full range (min-max)	0 to 97	0 to 88	0 to 92

<b>Reporting group values</b>	Arm D: Aza after	Total	
Number of subjects	99	268	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
median	62.3		
full range (min-max)	18 to 79	-	
Gender categorical			
Units: Subjects			
Female	39	124	
Male	60	144	
ECOG Performance Status			
Units: Subjects			
ECOG 0	42	113	
ECOG 1	47	136	
ECOG 2	10	19	
Type of AML			
Units: Subjects			
De Novo AML	76	197	
sAML	18	50	
tAML	5	21	
CEBPA mutation status			
Units: Subjects			
Wildtype	76	215	
Single mutation	2	6	
Double mutation	8	17	
Not recorded	13	30	
DNMT3A mutation status			
Units: Subjects			
Wildtype	72	195	
Mutation	11	40	
Not recorded	16	33	
ASXL1 mutation status			
Units: Subjects			
Wildtype	67	181	
Mutation	9	32	

Not recorded	23	55	
RUNX1 mutation status Units: Subjects			
Wildtype	69	187	
Mutation	14	46	
not recorded	16	35	
IDH1 mutation status Units: Subjects			
Wildtype	77	206	
Mutation	6	25	
not recorded	16	37	
IDH2 mutation status Units: Subjects			
Wildtype	63	188	
Mutation	13	27	
not recorded	23	53	
ELN 2010 classification Units: Subjects			
Favorable	6	14	
Intermediate-I	28	79	
Intermediate-II	23	60	
Adverse	31	77	
not applicable	11	38	
Hemoglobin (g/dl) Units: g/dl			
median	9.1		
full range (min-max)	5.6 to 13.8	-	
Platelets (G/l) Units: G/l			
median	67		
full range (min-max)	4 to 956	-	
White blood count (G/l) Units: G/l			
median	4.2		
full range (min-max)	0.3 to 214.0	-	
Bone marrow blasts (%) Units: percent			
median	60		
full range (min-max)	0 to 99	-	
Peripheral blood blasts (%) Units: percent			
median	8.5		
full range (min-max)	0 to 97	-	

### Subject analysis sets

Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis
Subject analysis set description:	
The full analysis set contained all patients scheduled for study treatment.	
Subject analysis set title	Primary endpoint analysis set

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Data of all patients scheduled for study treatment (n=268) were considered for efficacy and safety analyses. According to statistical analysis planning, 220 eligible patients were included into analysis of primary endpoint (= primary endpoint analysis set).

<b>Reporting group values</b>	Full analysis set	Primary endpoint analysis set	
Number of subjects	268	220	
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
median	62.6		
full range (min-max)	18 to 82		
Gender categorical Units: Subjects			
Female	124		
Male	144		
ECOG Performance Status Units: Subjects			
ECOG 0	113		
ECOG 1	136		
ECOG 2	19		
Type of AML Units: Subjects			
De Novo AML	197		
sAML	50		
tAML	21		
CEBPA mutation status Units: Subjects			
Wildtype	215		
Single mutation	6		
Double mutation	17		
Not recorded	30		
DNMT3A mutation status Units: Subjects			
Wildtype	195		
Mutation	40		
Not recorded	33		
ASXL1 mutation status Units: Subjects			

Wildtype	181		
Mutation	32		
Not recorded	55		
RUNX1 mutation status			
Units: Subjects			
Wildtype	187		
Mutation	46		
not recorded	35		
IDH1 mutation status			
Units: Subjects			
Wildtype	206		
Mutation	25		
not recorded	37		
IDH2 mutation status			
Units: Subjects			
Wildtype	188		
Mutation	27		
not recorded	53		
ELN 2010 classification			
Units: Subjects			
Favorable	14		
Intermediate-I	79		
Intermediate-II	60		
Adverse	77		
not applicable	38		
Hemoglobin (g/dl)			
Units: g/dl			
median	9.2		
full range (min-max)	5.2 to 13.8		
Platelets (G/l)			
Units: G/l			
median	63.5		
full range (min-max)	3 to 1286		
White blood count (G/l)			
Units: G/l			
median	3.7		
full range (min-max)	0.3 to 214.0		
Bone marrow blasts (%)			
Units: percent			
median	60		
full range (min-max)	0 to 100		
Peripheral blood blasts (%)			
Units: percent			
median	10		
full range (min-max)	0 to 97		

## End points

### End points reporting groups

Reporting group title	Arm A: Standard
Reporting group description: -	
Reporting group title	Arm B: Aza prior
Reporting group description: -	
Reporting group title	Arm C: Aza concurrent
Reporting group description: -	
Reporting group title	Arm D: Aza after
Reporting group description: -	
Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis
Subject analysis set description: The full analysis set contained all patients scheduled for study treatment.	
Subject analysis set title	Primary endpoint analysis set
Subject analysis set type	Intention-to-treat
Subject analysis set description: Data of all patients scheduled for study treatment (n=268) were considered for efficacy and safety analyses. According to statistical analysis planning, 220 eligible patients were included into analysis of primary endpoint (= primary endpoint analysis set).	

### Primary: CR rate after induction therapy (primary endpoint analysis set)

End point title	CR rate after induction therapy (primary endpoint analysis)
End point description: The null hypothesis in each arm was $H_0: \pi \leq 0.40$ , whereby $\pi$ denoted the true CR rate of the induction therapy. In contrast, an effective therapy should achieve at least a CR rate of 55%. The sample size was calculated to detect an effective therapy with a power of 80%. The level of significance was fixed at $\alpha=5\%$ for each treatment arm. Based on the „optimal two-stage design“ of Simon, an efficacy of the corresponding therapy would be rejected in the first stage of 26 treated patients, if 11 or less patients achieved a CR (or CRi). If 12 or more patients achieved a CR (or CRi) during this first stage, the trial would be continued to second stage with a total sample size of 84 patients per treatment arm. If more than 40 of 84 evaluable patients achieved a CR (or CRi), the null hypothesis of the corresponding treatment arm could be rejected and the treatment arm could be judged as effective therapy.	
End point type	Primary
End point timeframe: after induction therapy (two months)	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Primary endpoint was analyzed according to Simon's two stage design. An effective therapy should have achieved a CR in more than 40 of 84 patients. The null hypothesis for treatment arm D could not be rejected, since there were only 37 patients who achieved a CR/CRi. Since 45 patients achieved a CR/CRi in arm A, the standard arm was judged as the sole effective treatment arm of the study with an estimated CR rate of 55.5% and a lower limit of a one-sided 95% confidence interval of 46.3%.

End point values	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	84	26	26	84
Units: Subjects with Complete remission	45	11	10	37

<b>End point values</b>	Primary endpoint analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	220			
Units: Subjects with Complete remission	103			

### Statistical analyses

No statistical analyses for this end point

### Secondary: CR rate after induction therapy (full data set)

End point title	CR rate after induction therapy (full data set)
End point description:	
End point type	Secondary
End point timeframe:	
CR rate after induction therapy (two months)	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	35	34	99
Units: Subjects with complete remission	54	14	12	46

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	268			
Units: Subjects with complete remission	126			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Event-free Survival after four years

End point title	Event-free Survival after four years
End point description:	
As events the following were considered according to study protocol: death during induction therapy,	

refractory disease after first induction therapy, refractory disease or partial response after second induction therapy, relapse and death in CR. Time between study entry and occurrence of the first event was analyzed.

End point type	Secondary
End point timeframe: after four years	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	35	34	99
Units: Percentage				
number (confidence interval 95%)	23.8 (16.6 to 34.2)	8.6 (2.9 to 25.3)	19.0 (9.3 to 38.7)	10.1 (5.6 to 18.2)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	268			
Units: Percentage				
number (confidence interval 95%)	16.1 (12.2 to 21.2)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Relapse-free Survival after four years

End point title	Relapse-free Survival after four years
End point description:	
End point type	Secondary
End point timeframe: after four years	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	54	14	12	46
Units: Percentage				
number (confidence interval 95%)	36.0 (25.1 to 51.7)	21.4 (7.9 to 58.4)	41.7 (21.3 to 81.4)	21.7 (12.6 to 37.6)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	126			
Units: Percentage				
number (confidence interval 95%)	29.8 (22.8 to 39.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Cumulative incidence of relapse

End point title	Cumulative incidence of relapse
End point description:	
End point type	Secondary
End point timeframe: after four years	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	54	14	12	46
Units: Percentage				
number (not applicable)	50.9	57.1	50.0	60.9

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	126			
Units: Percentage				
number (not applicable)	55.0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Cumulative incidence of death

End point title	Cumulative incidence of death
End point description:	
End point type	Secondary
End point timeframe: after four years	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	54	14	12	46
Units: Percentage				
number (not applicable)	13.1	21.4	8.3	17.4

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	126			
Units: Percentage				
number (not applicable)	15.2			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival after four years

End point title	Overall survival after four years
End point description:	
End point type	Secondary
End point timeframe: after four years	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	35	34	99
Units: Percentage				
number (confidence interval 95%)	36.6 (28.1 to 47.6)	20.0 (10.3 to 38.8)	29.4 (17.5 to 49.5)	25.5 (4.5 to 38.1)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	268			
Units: Percentage				
number (confidence interval 95%)	29.4 (24.3 to 35.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Nights in hospital (overall trial)

End point title	Nights in hospital (overall trial)
End point description:	
End point type	Secondary
End point timeframe:	
Whole Trial (max. 30 months)	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	35	34	99
Units: Nights				
median (full range (min-max))	65 (16 to 171)	40 (14 to 150)	43.5 (18 to 156)	58 (3 to 172)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	268			
Units: Nights				
median (full range (min-max))	55 (3 to 172)			

### Statistical analyses

No statistical analyses for this end point

**Secondary: Median duration of Leukopenia after consolidation therapy**

End point title	Median duration of Leukopenia after consolidation therapy
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

within the first six months of therapy

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	4	7	24
Units: Days				
number (not applicable)				
Consolidation cycle 1	16	16	14	15.5
Consolidation cycle 2	17	15	15	15
Consolidation cycle 3	17.5	15	22.5	15

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Median duration of neutropenia after consolidation therapy**

End point title	Median duration of neutropenia after consolidation therapy
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

within the first six months of therapy

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	22	3	7	22
Units: Days				
number (not applicable)				
Consolidation cycle 1	18	16	24	18
Consolidation cycle 2	18	16	16	15
Consolidation cycle 3	19.5	17	27	17

**Statistical analyses**

No statistical analyses for this end point

### Secondary: Median duration of thrombocytopenia after consolidation therapy

End point title | Median duration of thrombocytopenia after consolidation therapy

End point description:

End point type | Secondary

End point timeframe:

within the first six months of therapy

End point values	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	4	7	24
Units: Days				
number (not applicable)				
Consolidation cycle 1	22	20	17	16
Consolidation cycle 2	28	18	19	18
Consolidation cycle 3	20	17	23.5	16.5

### Statistical analyses

No statistical analyses for this end point

### Secondary: Quality of Health (Global health status)

End point title | Quality of Health (Global health status)

End point description:

End point type | Secondary

End point timeframe:

at baseline and at the end of Treatment (maximal after 30 months)

End point values	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	33	4	7	37
Units: Score value %				
median (full range (min-max))				
Baseline	50 (16.7 to 83.3)	54.2 (16.7 to 100)	33.3 (16.7 to 100)	50 (0 to 100)
End of treatment	75 (16.7 to 100)	41.7 (16.7 to 50)	41.7 (41.7 to 41.7)	58.3 (33.3 to 83.3)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	81			
Units: Score value %				
median (full range (min-max))				
Baseline	50 (0 to 100)			
End of treatment	66.7 (16.7 to 100)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Rate of Early / Hypoplastic Death (ED/HD)

End point title	Rate of Early / Hypoplastic Death (ED/HD)
End point description:	
End point type	Secondary
End point timeframe:	
within the first two months of therapy (induction therapy)	

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	35	34	99
Units: Rate				
number (confidence interval 95%)	2.0 (0.6 to 7.0)	5.7 (1.6 to 18.6)	5.9 (1.6 to 19.0)	6.0 (2.8 to 12.6)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	268			
Units: Rate				
number (confidence interval 95%)	4.5 (2.6 to 7.7)			

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Median duration of leukopenia after induction therapy**

---

End point title | Median duration of leukopenia after induction therapy

End point description:

End point type | Secondary

End point timeframe:

within the first two months (induction therapy)

---

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	34	34	98
Units: Days				
number (not applicable)				
Induction cycle 1	24	27	25	27
Induction cycle 2	26	26	25	25

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Median duration of neutropenia after induction therapy**

---

End point title | Median duration of neutropenia after induction therapy

End point description:

End point type | Secondary

End point timeframe:

within the first two months (induction therapy)

---

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	82	28	29	81
Units: Days				
number (not applicable)				
Induction cycle 1	31	30	40	33
Induction cycle 2	36	31	35	35

## Statistical analyses

No statistical analyses for this end point

### Secondary: Median duration of thrombocytopenia after induction therapy

End point title | Median duration of thrombocytopenia after induction therapy

End point description:

End point type | Secondary

End point timeframe:

within the first two months (induction therapy)

<b>End point values</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent	Arm D: Aza after
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	34	34	98
Units: Days				
number (not applicable)				
Induction cycle 1	25	29	28	22
Induction cycle 2	26	23	25	19

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

The adverse event reporting period for this trial began upon signing of informed consent and ended 28 days after the last treatment Administration.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
Dictionary version	3.0

### Reporting groups

Reporting group title	Arm A: Standard
Reporting group description: -	
Reporting group title	Arm B: Aza prior
Reporting group description: -	
Reporting group title	Arm C: Aza concurrent
Reporting group description: -	
Reporting group title	Arm D: Aza after
Reporting group description: -	

<b>Serious adverse events</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent
Total subjects affected by serious adverse events			
subjects affected / exposed	30 / 100 (30.00%)	11 / 35 (31.43%)	12 / 34 (35.29%)
number of deaths (all causes)	4	3	2
number of deaths resulting from adverse events	4	3	2
Vascular disorders			
CNS Hemorrhage			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage pulmonary			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GU			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis/embolism			

subjects affected / exposed	0 / 100 (0.00%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			
Constitutional symptoms - other			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death not associated with CTCAE			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Immune system disorders</b>			
Allergic reaction			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Allergy - Other			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytes			
subjects affected / exposed	2 / 100 (2.00%)	1 / 35 (2.86%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	2 / 2	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
ARDS			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnea			

subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 100 (0.00%)	1 / 35 (2.86%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 100 (0.00%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Supraventricular arrhythmia			
subjects affected / exposed	2 / 100 (2.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac general - other			
subjects affected / exposed	2 / 100 (2.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac ischemia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary arrest			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			

subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Confusion			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Blood - Other			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow cellularity			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemoglobin			

subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutrophils</b>			
subjects affected / exposed	1 / 100 (1.00%)	1 / 35 (2.86%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Platelets</b>			
subjects affected / exposed	2 / 100 (2.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	2 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Splenic function</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eye disorders</b>			
<b>Retinal detachment</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Colitis</b>			
subjects affected / exposed	2 / 100 (2.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	2 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Diarrhea</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Enteritis</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ileus</b>			

subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Mucositis</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pain - Gastrointestinal: Abdomen NOS</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
<b>Cholecystitis</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary - other</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Liver dysfunction</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
<b>Pancreatitis</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Dermatology - Other</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rash			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Cystitis			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal - other			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal - other: Fluid retention/edema			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Diabetes			
subjects affected / exposed	0 / 100 (0.00%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Musculoskeletal - other			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Musculoskeletal: joint			

subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Febrile neutropenia</b>			
subjects affected / exposed	3 / 100 (3.00%)	2 / 35 (5.71%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	2 / 3	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection - Catheter-related</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection - Gastrointestinal Abdomen NOS</b>			
subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection - Gastrointestinal anal/perianal</b>			
subjects affected / exposed	0 / 100 (0.00%)	2 / 35 (5.71%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection - Gastrointestinal - Appendix</b>			
subjects affected / exposed	2 / 100 (2.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection - other</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sepsis</b>			
subjects affected / exposed	5 / 100 (5.00%)	3 / 35 (8.57%)	5 / 34 (14.71%)
occurrences causally related to treatment / all	4 / 5	0 / 3	3 / 5
deaths causally related to treatment / all	1 / 2	0 / 2	1 / 2

Infection with grade 3/4 neutrophils subjects affected / exposed	1 / 100 (1.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection - Soft tissue NOS subjects affected / exposed	0 / 100 (0.00%)	2 / 35 (5.71%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung (Pneumonia) subjects affected / exposed	5 / 100 (5.00%)	1 / 35 (2.86%)	3 / 34 (8.82%)
occurrences causally related to treatment / all	4 / 5	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Metabolism and nutrition disorders Hypokalemia subjects affected / exposed	0 / 100 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Arm D: Aza after		
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 99 (32.32%)		
number of deaths (all causes)	8		
number of deaths resulting from adverse events	8		
Vascular disorders CNS Hemorrhage subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hemorrhage pulmonary subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hemorrhage, GU			

subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis/embolism			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Constitutional symptoms - other			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death not associated with CTCAE			
subjects affected / exposed	3 / 99 (3.03%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 3		
Immune system disorders			
Allergic reaction			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Allergy - Other			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukocytes			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
ARDS			

subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
<b>Dyspnea</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Pneumothorax</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pneumonia</b>			
subjects affected / exposed	2 / 99 (2.02%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
<b>Supraventricular arrhythmia</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Ventricular arrhythmia</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac general - other</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac ischemia</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cardiopulmonary arrest</b>			

subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypertension</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypotension</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pericardial effusion</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Restrictive cardiomyopathy</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
<b>Confusion</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Seizure</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>Blood - Other</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Bone marrow cellularity</b>			

subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hemoglobin</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Neutrophils</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Platelets</b>			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Splenic function</b>			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Eye disorders</b>			
Retinal detachment			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Gastrointestinal disorders</b>			
Colitis			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Diarrhea			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enteritis			

subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Mucositis			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Gastrointestinal: Abdomen NOS			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary - other			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Liver dysfunction			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			

Dermatology - Other			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Cystitis			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal - other			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal - other: Fluid retention/edema			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	2 / 99 (2.02%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Diabetes			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Musculoskeletal - other			

subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pain - Musculoskeletal: joint			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Infections and infestations</b>			
Febrile neutropenia			
subjects affected / exposed	3 / 99 (3.03%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Infection - Catheter-related			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection - Gastrointestinal Abdomen NOS			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection - Gastrointestinal anal/perianal			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infection - Gastrointestinal - Appendix			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection - other			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Sepsis			
subjects affected / exposed	9 / 99 (9.09%)		
occurrences causally related to treatment / all	5 / 9		
deaths causally related to treatment / all	2 / 3		
Infection with grade 3/4 neutrophils			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection - Soft tissue NOS			
subjects affected / exposed	0 / 99 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung (Pneumonia)			
subjects affected / exposed	4 / 99 (4.04%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypokalemia			
subjects affected / exposed	1 / 99 (1.01%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Arm A: Standard	Arm B: Aza prior	Arm C: Aza concurrent
Total subjects affected by non-serious adverse events			
subjects affected / exposed	100 / 100 (100.00%)	35 / 35 (100.00%)	34 / 34 (100.00%)
Vascular disorders			
Hematoma			
subjects affected / exposed	15 / 100 (15.00%)	2 / 35 (5.71%)	4 / 34 (11.76%)
occurrences (all)	27	2	5
Hemorrhage pulmonary			
subjects affected / exposed	22 / 100 (22.00%)	3 / 35 (8.57%)	7 / 34 (20.59%)
occurrences (all)	31	3	10

Hemorrhage, GI subjects affected / exposed occurrences (all)	5 / 100 (5.00%) 7	3 / 35 (8.57%) 4	2 / 34 (5.88%) 2
Petechiae subjects affected / exposed occurrences (all)	17 / 100 (17.00%) 30	7 / 35 (20.00%) 9	7 / 34 (20.59%) 10
Phlebitis subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 7	7 / 35 (20.00%) 10	2 / 34 (5.88%) 2
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	22 / 100 (22.00%) 39	7 / 35 (20.00%) 9	6 / 34 (17.65%) 9
Fever neonatal subjects affected / exposed occurrences (all)	38 / 100 (38.00%) 87	8 / 35 (22.86%) 23	11 / 34 (32.35%) 13
Insomnia subjects affected / exposed occurrences (all)	35 / 100 (35.00%) 84	6 / 35 (17.14%) 12	9 / 34 (26.47%) 15
Rigors/chills subjects affected / exposed occurrences (all)	8 / 100 (8.00%) 10	0 / 35 (0.00%) 0	5 / 34 (14.71%) 5
Weight gain subjects affected / exposed occurrences (all)	22 / 100 (22.00%) 36	4 / 35 (11.43%) 6	3 / 34 (8.82%) 6
Pain NOS subjects affected / exposed occurrences (all)	18 / 100 (18.00%) 23	5 / 35 (14.29%) 5	8 / 34 (23.53%) 16
Pain - other subjects affected / exposed occurrences (all)	8 / 100 (8.00%) 10	3 / 35 (8.57%) 3	4 / 34 (11.76%) 5
Immune system disorders			
Allergic reaction subjects affected / exposed occurrences (all)	19 / 100 (19.00%) 23	5 / 35 (14.29%) 7	4 / 34 (11.76%) 10
Respiratory, thoracic and mediastinal disorders			

Pain chest/thorax subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 7	4 / 35 (11.43%) 4	2 / 34 (5.88%) 3
Pain throat/pharynx subjects affected / exposed occurrences (all)	8 / 100 (8.00%) 9	1 / 35 (2.86%) 1	1 / 34 (2.94%) 1
Cough subjects affected / exposed occurrences (all)	12 / 100 (12.00%) 15	4 / 35 (11.43%) 6	5 / 34 (14.71%) 5
Dyspnea subjects affected / exposed occurrences (all)	11 / 100 (11.00%) 18	4 / 35 (11.43%) 5	5 / 34 (14.71%) 8
<b>Investigations</b>			
Coagulation - other subjects affected / exposed occurrences (all)	10 / 100 (10.00%) 13	3 / 35 (8.57%) 3	3 / 34 (8.82%) 5
ALT subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 14	2 / 35 (5.71%) 2	3 / 34 (8.82%) 5
AST subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 10	2 / 35 (5.71%) 3	2 / 34 (5.88%) 5
Bilirubin subjects affected / exposed occurrences (all)	14 / 100 (14.00%) 19	1 / 35 (2.86%) 1	2 / 34 (5.88%) 2
Creatinine subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 9	2 / 35 (5.71%) 3	3 / 34 (8.82%) 5
Hyperglycemia subjects affected / exposed occurrences (all)	5 / 100 (5.00%) 6	1 / 35 (2.86%) 1	1 / 34 (2.94%) 1
Hyperuricemia subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 8	2 / 35 (5.71%) 3	4 / 34 (11.76%) 4
Hypocalcemia			

subjects affected / exposed occurrences (all)	9 / 100 (9.00%) 14	1 / 35 (2.86%) 3	1 / 34 (2.94%) 1
Hypokalemia subjects affected / exposed occurrences (all)	57 / 100 (57.00%) 115	8 / 35 (22.86%) 20	12 / 34 (35.29%) 22
Hypomagnesemia subjects affected / exposed occurrences (all)	9 / 100 (9.00%) 14	2 / 35 (5.71%) 2	2 / 34 (5.88%) 2
Hyponatremia subjects affected / exposed occurrences (all)	5 / 100 (5.00%) 6	0 / 35 (0.00%) 0	4 / 34 (11.76%) 4
Investigations: other subjects affected / exposed occurrences (all)	14 / 100 (14.00%) 36	2 / 35 (5.71%) 7	3 / 34 (8.82%) 4
CRP increase subjects affected / exposed occurrences (all)	15 / 100 (15.00%) 25	3 / 35 (8.57%) 10	5 / 34 (14.71%) 9
Cardiac disorders			
Supraventricular arrhythmia subjects affected / exposed occurrences (all)	8 / 100 (8.00%) 11	3 / 35 (8.57%) 3	7 / 34 (20.59%) 9
Hypertension subjects affected / exposed occurrences (all)	24 / 100 (24.00%) 33	9 / 35 (25.71%) 10	6 / 34 (17.65%) 18
Hypotension subjects affected / exposed occurrences (all)	9 / 100 (9.00%) 11	1 / 35 (2.86%) 1	2 / 34 (5.88%) 2
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	18 / 100 (18.00%) 28	7 / 35 (20.00%) 7	6 / 34 (17.65%) 6
Agitation subjects affected / exposed occurrences (all)	5 / 100 (5.00%) 6	3 / 35 (8.57%) 3	3 / 34 (8.82%) 3
Anxiety			

subjects affected / exposed occurrences (all)	11 / 100 (11.00%) 19	4 / 35 (11.43%) 5	5 / 34 (14.71%) 5
Depression subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 11	5 / 35 (14.29%) 8	6 / 34 (17.65%) 7
Head/Headache subjects affected / exposed occurrences (all)	25 / 100 (25.00%) 44	9 / 35 (25.71%) 17	5 / 34 (14.71%) 7
Blood and lymphatic system disorders			
Hemoglobin subjects affected / exposed occurrences (all)	95 / 100 (95.00%) 247	28 / 35 (80.00%) 53	28 / 34 (82.35%) 63
Leukocytes subjects affected / exposed occurrences (all)	72 / 100 (72.00%) 180	24 / 35 (68.57%) 48	25 / 34 (73.53%) 62
Neutrophils subjects affected / exposed occurrences (all)	38 / 100 (38.00%) 94	15 / 35 (42.86%) 28	14 / 34 (41.18%) 31
Platelets subjects affected / exposed occurrences (all)	95 / 100 (95.00%) 256	29 / 35 (82.86%) 55	28 / 34 (82.35%) 73
Gastrointestinal disorders			
Anorexia subjects affected / exposed occurrences (all)	16 / 100 (16.00%) 20	5 / 35 (14.29%) 5	4 / 34 (11.76%) 7
Constipation subjects affected / exposed occurrences (all)	38 / 100 (38.00%) 61	12 / 35 (34.29%) 16	10 / 34 (29.41%) 19
Diarrhea subjects affected / exposed occurrences (all)	51 / 100 (51.00%) 89	13 / 35 (37.14%) 20	11 / 34 (32.35%) 17
Heartburn subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 12	1 / 35 (2.86%) 2	4 / 34 (11.76%) 6
Mucositis			

subjects affected / exposed occurrences (all)	39 / 100 (39.00%) 56	8 / 35 (22.86%) 10	13 / 34 (38.24%) 16
Nausea subjects affected / exposed occurrences (all)	61 / 100 (61.00%) 128	18 / 35 (51.43%) 33	23 / 34 (67.65%) 51
Vomiting subjects affected / exposed occurrences (all)	28 / 100 (28.00%) 40	10 / 35 (28.57%) 12	15 / 34 (44.12%) 22
Pain Abdomen NOS subjects affected / exposed occurrences (all)	22 / 100 (22.00%) 32	6 / 35 (17.14%) 7	5 / 34 (14.71%) 5
Pain Stomach subjects affected / exposed occurrences (all)	10 / 100 (10.00%) 14	8 / 35 (22.86%) 9	4 / 34 (11.76%) 5
Skin and subcutaneous tissue disorders Dermatology - other subjects affected / exposed occurrences (all)	11 / 100 (11.00%) 15	4 / 35 (11.43%) 8	2 / 34 (5.88%) 6
Injection site reaction subjects affected / exposed occurrences (all)	15 / 100 (15.00%) 23	8 / 35 (22.86%) 12	9 / 34 (26.47%) 24
Pruritus subjects affected / exposed occurrences (all)	11 / 100 (11.00%) 17	2 / 35 (5.71%) 3	2 / 34 (5.88%) 2
Rash subjects affected / exposed occurrences (all)	31 / 100 (31.00%) 57	9 / 35 (25.71%) 16	11 / 34 (32.35%) 16
Renal and urinary disorders Fluid retention/edema subjects affected / exposed occurrences (all)	53 / 100 (53.00%) 89	12 / 35 (34.29%) 30	17 / 34 (50.00%) 32
Musculoskeletal and connective tissue disorders Musculoskeletal - other subjects affected / exposed occurrences (all)	5 / 100 (5.00%) 6	3 / 35 (8.57%) 3	1 / 34 (2.94%) 1
Pain back			

subjects affected / exposed occurrences (all)	17 / 100 (17.00%) 23	3 / 35 (8.57%) 3	3 / 34 (8.82%) 4
Pain bone subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 9	2 / 35 (5.71%) 2	1 / 34 (2.94%) 1
Pain Extremity/Limb subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 8	2 / 35 (5.71%) 2	2 / 34 (5.88%) 2
Pain: Joint subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 7	4 / 35 (11.43%) 4	1 / 34 (2.94%) 1
<b>Infections and infestations</b>			
Infection: Lip/perioral subjects affected / exposed occurrences (all)	9 / 100 (9.00%) 12	4 / 35 (11.43%) 4	1 / 34 (2.94%) 1
Febrile neutropenia subjects affected / exposed occurrences (all)	52 / 100 (52.00%) 91	18 / 35 (51.43%) 24	16 / 34 (47.06%) 27
Infection: Catheter-related subjects affected / exposed occurrences (all)	12 / 100 (12.00%) 17	9 / 35 (25.71%) 10	3 / 34 (8.82%) 5
Infection - other subjects affected / exposed occurrences (all)	32 / 100 (32.00%) 58	5 / 35 (14.29%) 8	6 / 34 (17.65%) 7
Sepsis subjects affected / exposed occurrences (all)	23 / 100 (23.00%) 36	5 / 35 (14.29%) 9	8 / 34 (23.53%) 14
Infection with grade 3/4 neutrophils subjects affected / exposed occurrences (all)	8 / 100 (8.00%) 13	1 / 35 (2.86%) 1	1 / 34 (2.94%) 1
Infection with unknown ANC subjects affected / exposed occurrences (all)	5 / 100 (5.00%) 11	2 / 35 (5.71%) 2	1 / 34 (2.94%) 3
Lung (pneumonia) subjects affected / exposed occurrences (all)	23 / 100 (23.00%) 35	9 / 35 (25.71%) 11	4 / 34 (11.76%) 9

Infection: Urinary tract NOS subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 11	1 / 35 (2.86%) 1	3 / 34 (8.82%) 3
--	-----------------------	---------------------	---------------------

<b>Non-serious adverse events</b>	Arm D: Aza after		
Total subjects affected by non-serious adverse events subjects affected / exposed	99 / 99 (100.00%)		
Vascular disorders			
Hematoma subjects affected / exposed occurrences (all)	9 / 99 (9.09%) 9		
Hemorrhage pulmonary subjects affected / exposed occurrences (all)	20 / 99 (20.20%) 27		
Hemorrhage, GI subjects affected / exposed occurrences (all)	6 / 99 (6.06%) 9		
Petechiae subjects affected / exposed occurrences (all)	19 / 99 (19.19%) 21		
Phlebitis subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 10		
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	19 / 99 (19.19%) 26		
Fever neonatal subjects affected / exposed occurrences (all)	33 / 99 (33.33%) 53		
Insomnia subjects affected / exposed occurrences (all)	38 / 99 (38.38%) 52		
Rigors/chills subjects affected / exposed occurrences (all)	1 / 99 (1.01%) 1		
Weight gain			

<p>subjects affected / exposed occurrences (all)</p> <p>Pain NOS subjects affected / exposed occurrences (all)</p> <p>Pain - other subjects affected / exposed occurrences (all)</p>	<p>13 / 99 (13.13%) 19</p> <p>8 / 99 (8.08%) 8</p> <p>6 / 99 (6.06%) 7</p>		
<p>Immune system disorders Allergic reaction subjects affected / exposed occurrences (all)</p>	<p>19 / 99 (19.19%) 28</p>		
<p>Respiratory, thoracic and mediastinal disorders Pain chest/thorax subjects affected / exposed occurrences (all)</p> <p>Pain throat/pharynx subjects affected / exposed occurrences (all)</p> <p>Cough subjects affected / exposed occurrences (all)</p> <p>Dyspnea subjects affected / exposed occurrences (all)</p>	<p>3 / 99 (3.03%) 3</p> <p>8 / 99 (8.08%) 9</p> <p>25 / 99 (25.25%) 29</p> <p>12 / 99 (12.12%) 15</p>		
<p>Investigations Coagulation - other subjects affected / exposed occurrences (all)</p> <p>ALT subjects affected / exposed occurrences (all)</p> <p>AST subjects affected / exposed occurrences (all)</p> <p>Bilirubin</p>	<p>5 / 99 (5.05%) 7</p> <p>4 / 99 (4.04%) 4</p> <p>2 / 99 (2.02%) 2</p>		

subjects affected / exposed occurrences (all)	6 / 99 (6.06%) 6		
<b>Creatinine</b> subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 12		
<b>Hyperglycemia</b> subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 11		
<b>Hyperuricemia</b> subjects affected / exposed occurrences (all)	4 / 99 (4.04%) 4		
<b>Hypocalcemia</b> subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 11		
<b>Hypokalemia</b> subjects affected / exposed occurrences (all)	38 / 99 (38.38%) 67		
<b>Hypomagnesemia</b> subjects affected / exposed occurrences (all)	13 / 99 (13.13%) 14		
<b>Hyponatremia</b> subjects affected / exposed occurrences (all)	4 / 99 (4.04%) 6		
<b>Investigations: other</b> subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 13		
<b>CRP increase</b> subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 6		
<b>Cardiac disorders</b>			
Supraventricular arrhythmia subjects affected / exposed occurrences (all)	12 / 99 (12.12%) 18		
Hypertension subjects affected / exposed occurrences (all)	19 / 99 (19.19%) 27		

Hypotension subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 7		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	11 / 99 (11.11%) 18		
Agitation subjects affected / exposed occurrences (all)	6 / 99 (6.06%) 8		
Anxiety subjects affected / exposed occurrences (all)	9 / 99 (9.09%) 11		
Depression subjects affected / exposed occurrences (all)	17 / 99 (17.17%) 19		
Head/Headache subjects affected / exposed occurrences (all)	19 / 99 (19.19%) 25		
Blood and lymphatic system disorders Hemoglobin subjects affected / exposed occurrences (all)	85 / 99 (85.86%) 214		
Leukocytes subjects affected / exposed occurrences (all)	70 / 99 (70.71%) 192		
Neutrophils subjects affected / exposed occurrences (all)	42 / 99 (42.42%) 80		
Platelets subjects affected / exposed occurrences (all)	87 / 99 (87.88%) 234		
Gastrointestinal disorders Anorexia subjects affected / exposed occurrences (all)	12 / 99 (12.12%) 16		
Constipation			

subjects affected / exposed	33 / 99 (33.33%)		
occurrences (all)	51		
Diarrhea			
subjects affected / exposed	38 / 99 (38.38%)		
occurrences (all)	57		
Heartburn			
subjects affected / exposed	7 / 99 (7.07%)		
occurrences (all)	9		
Mucositis			
subjects affected / exposed	43 / 99 (43.43%)		
occurrences (all)	49		
Nausea			
subjects affected / exposed	57 / 99 (57.58%)		
occurrences (all)	109		
Vomiting			
subjects affected / exposed	30 / 99 (30.30%)		
occurrences (all)	47		
Pain Abdomen NOS			
subjects affected / exposed	17 / 99 (17.17%)		
occurrences (all)	19		
Pain Stomach			
subjects affected / exposed	12 / 99 (12.12%)		
occurrences (all)	17		
Skin and subcutaneous tissue disorders			
Dermatology - other			
subjects affected / exposed	10 / 99 (10.10%)		
occurrences (all)	12		
Injection site reaction			
subjects affected / exposed	24 / 99 (24.24%)		
occurrences (all)	45		
Pruritus			
subjects affected / exposed	9 / 99 (9.09%)		
occurrences (all)	10		
Rash			
subjects affected / exposed	27 / 99 (27.27%)		
occurrences (all)	45		

Renal and urinary disorders Fluid retention/edema subjects affected / exposed occurrences (all)	42 / 99 (42.42%) 68		
Musculoskeletal and connective tissue disorders Musculoskeletal - other subjects affected / exposed occurrences (all)  Pain back subjects affected / exposed occurrences (all)  Pain bone subjects affected / exposed occurrences (all)  Pain Extremity/Limb subjects affected / exposed occurrences (all)  Pain: Joint subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 12  12 / 99 (12.12%) 16  6 / 99 (6.06%) 7  9 / 99 (9.09%) 16  8 / 99 (8.08%) 12		
Infections and infestations Infection: Lip/perioral subjects affected / exposed occurrences (all)  Febrile neutropenia subjects affected / exposed occurrences (all)  Infection: Catheter-related subjects affected / exposed occurrences (all)  Infection - other subjects affected / exposed occurrences (all)  Sepsis subjects affected / exposed occurrences (all)	12 / 99 (12.12%) 12  43 / 99 (43.43%) 73  13 / 99 (13.13%) 13  29 / 99 (29.29%) 42  14 / 99 (14.14%) 28		

Infection with grade 3/4 neutrophils subjects affected / exposed occurrences (all)	3 / 99 (3.03%) 3		
Infection with unknown ANC subjects affected / exposed occurrences (all)	11 / 99 (11.11%) 14		
Lung (pneumonia) subjects affected / exposed occurrences (all)	19 / 99 (19.19%) 29		
Infection: Urinary tract NOS subjects affected / exposed occurrences (all)	3 / 99 (3.03%) 3		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported